{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Bristol-Myers+Squibb",
    "query": {
      "sponsor": "Bristol-Myers Squibb"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 2013,
    "total_pages": 202,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Bristol-Myers+Squibb&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-07T08:59:40.071Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06345183",
      "title": "Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Advanced Renal Cell Carcinoma (aRCC)"
      ],
      "interventions": [
        {
          "name": "Nivolumab + Ipilimumab combination therapy",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Pembrolizumab + Lenvatinib combination therapy",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 327,
      "start_date": "2024-02-19",
      "completion_date": "2024-04-04",
      "has_results": false,
      "last_update_posted_date": "2025-11-06",
      "last_synced_at": "2026-06-07T08:59:40.071Z",
      "location_count": 1,
      "location_summary": "Dublin, Ohio",
      "locations": [
        {
          "city": "Dublin",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06345183"
    },
    {
      "nct_id": "NCT03472586",
      "title": "Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Malignant Neoplasm in the Liver",
        "Metastatic Uveal Melanoma",
        "Stage IV Uveal Melanoma AJCC v7"
      ],
      "interventions": [
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Embolization Therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2018-05-02",
      "completion_date": "2024-12-31",
      "has_results": true,
      "last_update_posted_date": "2025-04-24",
      "last_synced_at": "2026-06-07T08:59:40.071Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03472586"
    },
    {
      "nct_id": "NCT02927769",
      "title": "A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hodgkin Disease"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "brentuximab vedotin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "bendamustine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "5 Years to 30 Years"
      },
      "enrollment_count": 72,
      "start_date": "2017-03-28",
      "completion_date": "2024-05-28",
      "has_results": true,
      "last_update_posted_date": "2025-02-10",
      "last_synced_at": "2026-06-07T08:59:40.071Z",
      "location_count": 43,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 40 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Madera",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02927769"
    },
    {
      "nct_id": "NCT03414983",
      "title": "An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 196,
      "start_date": "2018-02-20",
      "completion_date": "2022-12-28",
      "has_results": true,
      "last_update_posted_date": "2023-11-18",
      "last_synced_at": "2026-06-07T08:59:40.071Z",
      "location_count": 35,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 29 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03414983"
    },
    {
      "nct_id": "NCT06240754",
      "title": "Enasidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH2A Decentralized Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Clonal Cytopenia of Undetermined Significance",
        "CCUS Clonal Cytopenia of Undetermined Significance"
      ],
      "interventions": [
        {
          "name": "Enasidenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2024-10-10",
      "completion_date": "2029-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-05-27",
      "last_synced_at": "2026-06-07T08:59:40.071Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06240754"
    },
    {
      "nct_id": "NCT00838890",
      "title": "A Study of BMS-863233 in Patients With Hematologic Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Refractory Hematologic Cancer"
      ],
      "interventions": [
        {
          "name": "Cdc7-inhibitor (BMS-863233)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2009-03",
      "completion_date": "2010-01",
      "has_results": false,
      "last_update_posted_date": "2015-10-12",
      "last_synced_at": "2026-06-07T08:59:40.071Z",
      "location_count": 4,
      "location_summary": "Miami, Florida • Tampa, Florida • Boston, Massachusetts + 1 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00838890"
    },
    {
      "nct_id": "NCT01875224",
      "title": "Comparison of NODAT in Kidney Transplant Patients Receiving Belatacept Versus Standard Immunosuppression",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "New Onset Diabetes After Transplant",
        "Kidney Transplantation"
      ],
      "interventions": [
        {
          "name": "Belatacept",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Arizona",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 32,
      "start_date": "2013-08",
      "completion_date": "2016-08",
      "has_results": false,
      "last_update_posted_date": "2013-06-11",
      "last_synced_at": "2026-06-07T08:59:40.071Z",
      "location_count": 1,
      "location_summary": "Tucson, Arizona",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01875224"
    },
    {
      "nct_id": "NCT05621096",
      "title": "Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "DLBCL - Diffuse Large B Cell Lymphoma",
        "High-grade B-cell Lymphoma",
        "Follicular Lymphoma",
        "Mediastinal Large B-cell Lymphoma",
        "Indolent B-Cell Non-Hodgkin Lymphoma",
        "Relapsed Non-Hodgkin Lymphoma",
        "Refractory Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Bridging radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "Liso-cel",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Post-infusion radiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "BIOLOGICAL"
      ],
      "sponsor": "University of Nebraska",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2023-03-21",
      "completion_date": "2027-09",
      "has_results": false,
      "last_update_posted_date": "2025-09-25",
      "last_synced_at": "2026-06-07T08:59:40.071Z",
      "location_count": 1,
      "location_summary": "Omaha, Nebraska",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05621096"
    },
    {
      "nct_id": "NCT07283705",
      "title": "A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Phase 2 Study",
        "BMS-986504",
        "MTAP-deleted Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "BMS-986504",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "mFOLFIRINOX",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2026-05-18",
      "completion_date": "2031-10-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-16",
      "last_synced_at": "2026-06-07T08:59:40.071Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07283705"
    },
    {
      "nct_id": "NCT01450761",
      "title": "Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Small Cell Lung Carcinoma"
      ],
      "interventions": [
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo matching Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1351,
      "start_date": "2011-12-13",
      "completion_date": "2017-05-17",
      "has_results": true,
      "last_update_posted_date": "2020-07-08",
      "last_synced_at": "2026-06-07T08:59:40.071Z",
      "location_count": 42,
      "location_summary": "Hot Springs, Arkansas • Auburn, California • La Jolla, California + 34 more",
      "locations": [
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Auburn",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01450761"
    }
  ]
}